The law change removes the federal requirement for practitioners to have a DATA-Waiver registration to prescribe buprenorphine for the treatment of opioid use disorder.
The medication is a non-steroidal anti-inflammatory drug indicated for the acute treatment of migraine attacks with or without aura, in adults 18 years of age or older.